摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-N-(diphenylmethyl)-2-iodoaniline | 540522-73-4

中文名称
——
中文别名
——
英文名称
4-chloro-N-(diphenylmethyl)-2-iodoaniline
英文别名
benzhydryl-(4-chloro-2-iodo-phenyl)-amine;benzhydryl-(4-chloro-2-iodophenyl)amine;N-benzhydryl-4-chloro-2-iodoaniline
4-chloro-N-(diphenylmethyl)-2-iodoaniline化学式
CAS
540522-73-4
化学式
C19H15ClIN
mdl
——
分子量
419.692
InChiKey
LBUHHTQUPVBUOR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    480.2±45.0 °C(Predicted)
  • 密度:
    1.569±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    6.4
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

SDS

SDS:f7d0745019a372319a6346cf95408017
查看

反应信息

  • 作为反应物:
    描述:
    4-chloro-N-(diphenylmethyl)-2-iodoaniline 在 bis-triphenylphosphine-palladium(II) chloride 、 palladium on activated charcoal 咪唑copper(l) iodide 、 sodium azide 、 偶氮二甲酸二异丙酯 、 dimethyl sulfide borane 、 四丁基氟化铵氢气碳酸氢钠三乙胺三苯基膦 作用下, 以 四氢呋喃甲醇二氯甲烷N,N-二甲基甲酰胺 为溶剂, 80.0 ℃ 、101.33 kPa 条件下, 反应 101.67h, 生成 methyl 3-{2-[2-{2-[(benzylsulfonyl)amino]ethyl}-5-chloro-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy}benzoate
    参考文献:
    名称:
    Discovery of Ecopladib, an Indole Inhibitor of Cytosolic Phospholipase Α2α
    摘要:
    The synthesis and structure-activity relationship of a series of indole inhibitors of cytosolic phospholipase A(2)alpha (cPLA(2)alpha, type IVA phospholipase) are described. Inhibitors of cPLA(2)alpha are predicted to be efficacious in treating asthma as well as the signs and symptoms of osteoarthritis, rheumatoid arthritis, and pain. The introduction of a benzyl sulfonamide substituent at C2 was found to impart improved potency of these inhibitors, and the SAR of these sulfonamide analogues is disclosed. Compound 123 (Ecopladib) is a sub-micromolar inhibitor of cPLA(2)alpha in the GLU micelle and rat whole blood assays. Compound 123 displayed oral efficacy in the rat carrageenan air pouch and rat carrageenan-induced paw edema models.
    DOI:
    10.1021/jm061131z
  • 作为产物:
    描述:
    2-碘-4-氯苯胺二苯基溴甲烷N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以97%的产率得到4-chloro-N-(diphenylmethyl)-2-iodoaniline
    参考文献:
    名称:
    Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
    摘要:
    这项发明提供了一种使用通式所示的取代吲哚化合物及其药用盐形式的方法。该发明提供了一种在哺乳动物中治疗或预防血栓形成,或预防血栓形成症状进展的化合物使用方法。
    公开号:
    US20080009485A1
点击查看最新优质反应信息

文献信息

  • Inhibitors of cytosolic phospholipase A2
    申请人:Wyeth
    公开号:US20030144282A1
    公开(公告)日:2003-07-31
    This invention provides substituted indole compounds of the general formula: 1 and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.
    这项发明提供了一般式如下的取代吲哚化合物: 1 及其药用可接受的盐形式,以及将这些化合物用作各种磷脂酶酶的抑制剂的方法,特别是磷脂酶A 2 酶,并用于医疗治疗、预防和抑制疼痛和炎症。
  • Process for the synthesis of a CPLA2 inhibitor
    申请人:Dehnhardt M. Christoph
    公开号:US20050070723A1
    公开(公告)日:2005-03-31
    A process for making a substituted indole compound, including the steps of: reacting the compounds in a non-protic polar solvent in the presence of a catalyst to form the intermediate compound wherein Ph and X are as defined herein; and then, heating this intermediate compound in the solvent in the presence of the catalyst to form the substituted indole compound The invention also includes compounds formed by this process.
    制备替代吲哚化合物的方法,包括以下步骤:在非质子极性溶剂中,在催化剂的存在下,使化合物发生反应,形成中间体化合物,其中Ph和X的定义如本文所述;然后,在溶剂中,在催化剂的存在下加热此中间体化合物,形成替代吲哚化合物。该发明还包括由此过程形成的化合物。
  • Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors
    申请人:Michalak S. Ronald
    公开号:US20060041005A1
    公开(公告)日:2006-02-23
    The present invention provides method for making a compound of formula 1: comprising the steps of reacting compounds of formulas 2 and 3: to produce a compound of formula 4: wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined as described herein. The compound of formula 4 is then converted to the compound of formula 1. The invention further comprises compounds of formulas 3 and 4 and methods for making compounds of formulas 3 and 4.
    本发明提供了制备化合物的方法,其化学式为1:包括以下步骤:将化合物的化学式为2和3反应,得到化合物的化学式为4:其中R1、R2、R3、R4和R5的定义如本文所述。化合物的化学式为4然后转化为化合物的化学式为1。本发明还包括化学式为3和4的化合物以及制备化学式为3和4的方法。
  • Advanced route for the synthesis of cPLA2 inhibitors
    申请人:Wu Yanzhong
    公开号:US20050020858A1
    公开(公告)日:2005-01-27
    A process for making a compound of formula (I) in which process the compound HC≡C—(CH 2 ) n —NH 2 is reacted with the compound R 1 —SO 2 Cl to produce an intermediate compound, which intermediate compound is then reacted with the compound of formula to produce the compound of formula (I), and compounds produced by the process of this invention. The terms R 1 , R 2 , R 3 , R 4 and n have the definitions set forth in the specification.
    一种制备式(I)化合物的方法,其中化合物HC≡C—(CH2)n—NH2与化合物R1—SO2Cl反应,生成中间体化合物,然后将该中间体化合物与式的化合物反应,从而产生式(I)的化合物,以及该发明的方法产生的化合物。术语R1、R2、R3、R4和n的定义在规范中说明。
  • [EN] PROCESS FOR THE SYNTHESIS C-2, C-3 SUBSTITUTED N-ALKYLATED INDOLES USEFUL AS CPLA2 INHIBITORS<br/>[FR] PROCEDE DE SYNTHESE D'INDOLES N-ALKYLES SUBSTITUES EN C-2, C-3 UTILES COMME INHIBITEURS DE LA CPLA2
    申请人:WYETH CORP
    公开号:WO2006023611A1
    公开(公告)日:2006-03-02
    The present invention provides method for making a compound of formula (1) comprising the steps of reacting compounds of formulas (2) and (3) to produce a compound of formula (4) wherein R1, R2, R3, R4 and R5 are defined as described herein. The compound of formula (4) is then converted to the compound of formula (1). The invention further comprises compounds of formula (3) and (4) and methods for making compounds of formulae (3) and (4).
    本发明提供了一种制备化合物(1)的方法,包括以下步骤:反应化合物(2)和(3)的化合物,以产生化合物(4),其中R1、R2、R3、R4和R5如本文所述。然后将化合物(4)转化为化合物(1)。本发明还涉及化合物(3)和(4)以及制备化合物(3)和(4)的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫